Macrocyclic inhibitors of atp citrate lyase

EP4801897A1Pending Publication Date: 2026-09-09ESPERION THERAPEUTICS INC

0 Cites 0 Cited by

Patent Information

Application Number: EP2024805729
Authority / Receiving Office: EP · EP
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2023-11-01
Filing Date: 2024-10-31
Publication Date: 2026-09-09

Application Information

Patent Timeline

01 Nov 2023

Priority

31 Oct 2024

Application

EP2024805729

09 Sep 2026

Publication

EP4801897A1

IPC: C07D291/08; C07D513/08; C07D513/18; C07D515/08; C07D515/18; A61P1/16; A61P3/10; A61P13/12; A61P29/00; A61P35/00; A61P37/00; A61K31/439

CPC: A61P35/00; A61P3/10; A61P1/16; A61P37/00; A61P29/00; A61P13/12; C07D515/08; C07D291/08

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

AI Technical Summary

Technical Problem

Current treatment options for metabolic and cardiovascular diseases associated with cholesterol and triglyceride metabolism are inadequate, and there is a need for new therapeutic strategies that target ATP-citrate lyase (ACLY) activity.

Method used

Development of macrocyclic inhibitors of ATP citrate lyase (ACLY) as therapeutic agents to treat conditions such as nonalcoholic fatty liver disease (NAFLD), type-2 diabetes, chronic kidney disease, inflammation, autoimmunity, and cancer.

Benefits of technology

The ACLY inhibitors effectively modulate ACLY activity, providing therapeutic benefits for various metabolic and cardiovascular disorders by inhibiting cholesterol synthesis and suppressing fatty acid biosynthesis.

✦ Generated by Eureka AI based on patent content.

Patent Text Reader

Abstract

The application relates to macrocyclic compounds of formula (I) which act as inhibitors of ATP citrate lyase (ACLY) useful for the treatment of conditions, diseases, and disorders associated with aberrant levels of lipids such as liver diseases, type-2 diabetes, inflammation, chronic kidney disease, autoimmunity and cancer.

Need to check novelty before this filing date? Find Prior Art